William H Crown

List of Publications by Year
in descending order

59 papers	3,884 citations	201674 27 h-index	149698 56 g-index
61 all docs	61 docs citations	61 times ranked	4624 citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 2020, 3, e1920622.	5.9	505
2	Optum Labs: Building A Novel Node In The Learning Health Care System. Health Affairs, 2014, 33, 1187-1194.	5.2	338
3	A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases. Value in Health, 2003, 6, 90-97.	0.3	328
4	Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits. Journal of Allergy and Clinical Immunology, 2002, 109, 57-62.	2.9	316
5	The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. Journal of Clinical Psychiatry, 2002, 63, 963-971.	2.2	291
6	Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. Value in Health, 2009, 12, 1062-1073.	0.3	234
7	Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genetics in Medicine, 2011, 13, 349-355.	2.4	221
8	Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research—The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. Value in Health, 2015, 18, 5-16.	0.3	152
9	Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research—Part 2: Report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force. Value in Health, 2015, 18, 147-160.	0.3	109
10	A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health, 2014, 17, 143-156.	0.3	96
11	The Cost Consequences of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2004, 65, 341-347.	2.2	96
12	Potential Application of Machine Learning in Health Outcomes Research and Some Statistical Cautions. Value in Health, 2015, 18, 137-140.	0.3	80
13	Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2017, 20, 310-319.	0.3	79
14	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value in Health, 2020, 23, 1128-1136.	0.3	68
15	The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. Value in Health, 2005, 8, 149-156.	0.3	61
16	Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. Journal of Affective Disorders, 1998, 47, 71-79.	4.1	56
17	Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods. Applied Health Economics and Health Policy, 2014, 12, 7-18.	2.1	56
18	The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Current Medical Research and Opinion, 2004, 20, 1929-1936.	1.9	53

#	Article	IF	Citations
19	The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. , 1998, 17, 1943-1958.		46
20	Some Cautions on the Use of Instrumental Variables Estimators in Outcomes Research: How Bias in Instrumental Variables Estimators Is Affected by Instrument Strength, Instrument Contamination, and Sample Size. Value in Health, 2011, 14, 1078-1084.	0.3	46
21	Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leukemia and Lymphoma, 2006, 47, 1535-1544.	1.3	41
22	Machine learning models to predict onset of dementia: A label learning approach. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 918-925.	3.7	41
23	Real-World Evidence, Causal Inference, and Machine Learning. Value in Health, 2019, 22, 587-592.	0.3	38
24	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2018, 21, 1019-1028.	0.3	36
25	Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics, 2016, 34, 115-126.	3.3	35
26	The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An Instrument to Assess Outcomes of Schizophrenia Care. Schizophrenia Bulletin, 2003, 29, 247-256.	4.3	34
27	Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go?. Journal of Comparative Effectiveness Research, 2014, 3, 63-78.	1.4	34
28	Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open, 2021, 4, e2130587.	5.9	28
29	The family impact and costs of migraine. American Journal of Managed Care, 2004, 10, 313-20.	1.1	28
30	Utilization and Cost of Health Care Services Associated with Primary Malignant Brain Tumors in the United States. Journal of Neuro-Oncology, 2006, 81, 61-65.	2.9	27
31	Seasonal versus Perennial Allergic Rhinitis: Drug and Medical Resource Use Patterns. Value in Health, 2003, 6, 448-456.	0.3	24
32	Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force. Value in Health, 2022, 25, 1063-1080.	0.3	24
33	Panel 3: Methodological Issues in Conducting Pharmacoeconomic Evaluations—Retrospective and Claims Database Studies. Value in Health, 1999, 2, 82-87.	0.3	23
34	Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Annals of Allergy, Asthma and Immunology, 2004, 92, 523-529.	1.0	22
35	The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy. Advances in Therapy, 2013, 30, 1128-1140.	2.9	22
36	Long-Term Costs of Treatment for Depression: Impact of Drug Selection and Guideline Adherence. Value in Health, 2001, 4, 295-307.	0.3	20

#	Article	IF	Citations
37	Deep neural network models for identifying incident dementia using claims and EHR datasets. PLoS ONE, 2020, 15, e0236400.	2.5	20
38	A retrospective claims analysis of the direct costs of stress urinary incontinence. International Urogynecology Journal, 2003, 14, 403-411.	1.4	18
39	Guidelines for selecting among different types of bootstraps. Current Medical Research and Opinion, 2006, 22, 799-808.	1.9	18
40	Healthcare utilization among women who undergo surgery for stress urinary incontinence. International Urogynecology Journal, 2004, 15, 154-159.	1.4	13
41	ThereÊ¼s a Reason They Call Them Dummy Variables. Pharmacoeconomics, 2010, 28, 947-955.	3.3	11
42	Looking to the Future: Incorporating Genomic Information into Disparities Research to Reduce Measurement Error and Selection Bias. Health Services Research, 2012, 47, 1387-1410.	2.0	10
43	Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Clinical Therapeutics, 1998, 20, 780-796.	2.5	9
44	Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder. Medical Care, 2020, 58, 919-926.	2.4	9
45	Predicting Onset of Dementia Using Clinical Notes and Machine Learning: Case-Control Study. JMIR Medical Informatics, 2020, 8, e17819.	2.6	9
46	SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study. Journal of Affective Disorders, 1999, 52, 111-119.	4.1	8
47	Melding Regulatory, Pharmaceutical Industry, and U.S. Payer Perspectives on Improving Approaches to Heterogeneity of Treatment Effect in Research and Practice. Value in Health, 2013, 16, S10-S15.	0.3	8
48	Issues in the registration of database studies. Journal of Clinical Epidemiology, 2020, 121, 29-31.	5.0	7
49	How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?. Value in Health, 2022, 25, 167-170.	0.3	7
50	Real-World Evidence: Understanding Sources of Variability Through Empirical Analysis. Value in Health, 2021, 24, 116-117.	0.3	6
51	Clinical and economic effects of suboptimally controlled asthma. Managed Care Interface, 2004, 17, 31-6.	0.2	6
52	Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models. Pharmacoeconomics, 2016, 34, 95-100.	3.3	5
53	Measuring the costs and benefits of pharmaceutical expenditures. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 467-475.	1.4	4
54	Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety. Managed Care Interface, 2002, 15, 24-30.	0.2	4

#	ARTICLE	IF	CITATIONS
55	The Potential Role of Constrained Optimization Methods in Healthcare Decision Making. Applied Health Economics and Health Policy, 2020, 18, 461-462.	2.1	2
56	Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies?. Journal of Comparative Effectiveness Research, 2015, 4, 455-463.	1.4	1
57	Working in the New Big Data World: Academic/Corporate Partnership Model. Computers in Health Care, 2017, , 157-180.	0.3	1
58	Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis. Pharmaceutical Statistics, 2020, 20, 952-964.	1.3	0
59	Decomposition analysis as a framework for understanding heterogeneity of treatment effects in nonâ€randomized health care studies. Pharmaceutical Statistics, 2021, 20, 945-951.	1.3	0